

CLEVELAND BIOLABS INC  
Form 8-K  
November 08, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): November 8, 2012**

**Cleveland BioLabs, Inc.**

(Exact Name of Issuer as Specified in Charter)

**DELAWARE**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**001-32954**  
(Commission File Number)

**20-0077155**  
(I.R.S. Employer Identification  
Number)

**73 High Street**  
**Buffalo, NY**  
(Address of Principal Executive Offices)

**(716) 849-6810**  
(Registrant's Telephone Number, Including Area Code)

**14203**  
(Zip Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

**Item 2.02. Results of Operations and Financial Condition.**

On November 8, 2012, Cleveland BioLabs, Inc. (the "Company") issued a press release announcing its third quarter 2012 financial results. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be

deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

**Item 9.01. Financial Statements and Exhibits.**

(d)

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated November 8, 2012

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cleveland BioLabs, Inc.**

Date: November 8, 2012

By: /s/ YAKOV KOGAN

Name: Yakov Kogan, Ph.D., M.B.A.

Title: Chief Executive Officer